Clinical profile of Spanish hepatitis C virus-infected treatment-naïve patients with compensated cirrhosis in the CREST study.
Perfil clínico de los pacientes españoles con Hepatitis C naïve con cirrosis compensada tratados en el estudio CREST.
España
Glecaprevir y Pibrentasvir
Hepatitis C
Spain
cirrosis hepática
duración de la terapia
duration of therapy
glecaprevir and pibrentasvir
liver cirrhosis
Journal
Gastroenterologia y hepatologia
ISSN: 0210-5705
Titre abrégé: Gastroenterol Hepatol
Pays: Spain
ID NLM: 8406671
Informations de publication
Date de publication:
12 Feb 2024
12 Feb 2024
Historique:
received:
31
05
2023
revised:
30
01
2024
accepted:
06
02
2024
medline:
15
2
2024
pubmed:
15
2
2024
entrez:
14
2
2024
Statut:
aheadofprint
Résumé
There are still patients with hepatitis C in Spain who have yet to be diagnosed, but their clinical profile is unclear. In 2021, 21.93% of patients diagnosed had cirrhosis and were mostly treatment-naïve. This sub-analysis describes the clinical profile of the 60 Spanish treatment-naïve patients with compensated cirrhosis who were included in the CREST study. Sixty percent of patients were male, median age 56 years, and 33% had a history of drug use. Almost three-quarters (71.3%) had more than one comorbidity and 78.3% took concomitant medication. At treatment initiation, median platelet count was 139 x 10 Treatment with glecaprevir/pibrentasvir for 8 weeks in this cohort of treatment-naïve patients with compensated cirrhosis in Spain was safe and effective. This information reinforces the use of this short antiviral regimen even when there is compensated cirrhosis, simplifying the approach to hepatitis C among those patients still to be diagnosed and treated in Spain.
Sections du résumé
BACKGROUND AND AIM OF THE STUDY
OBJECTIVE
There are still patients with hepatitis C in Spain who have yet to be diagnosed, but their clinical profile is unclear. In 2021, 21.93% of patients diagnosed had cirrhosis and were mostly treatment-naïve.
METHODS
METHODS
This sub-analysis describes the clinical profile of the 60 Spanish treatment-naïve patients with compensated cirrhosis who were included in the CREST study.
MAJOR RESULTS
RESULTS
Sixty percent of patients were male, median age 56 years, and 33% had a history of drug use. Almost three-quarters (71.3%) had more than one comorbidity and 78.3% took concomitant medication. At treatment initiation, median platelet count was 139 x 10
CONCLUSIONS
CONCLUSIONS
Treatment with glecaprevir/pibrentasvir for 8 weeks in this cohort of treatment-naïve patients with compensated cirrhosis in Spain was safe and effective. This information reinforces the use of this short antiviral regimen even when there is compensated cirrhosis, simplifying the approach to hepatitis C among those patients still to be diagnosed and treated in Spain.
Identifiants
pubmed: 38355095
pii: S0210-5705(24)00037-2
doi: 10.1016/j.gastrohep.2024.02.003
pii:
doi:
Types de publication
Journal Article
Langues
eng
spa
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Elsevier España, S.L.U. All rights reserved.